{
    "root": "311556e4-3d8b-cba5-e063-6394a90ac823",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Divalproex Sodium",
    "value": "20250324",
    "ingredients": [
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 112",
            "code": "X7XJ6RM9Q2",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3000",
            "code": "SA1B764746",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01390"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "VANILLIN",
            "code": "CHI530446X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_18346"
        },
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        },
        {
            "name": "D&C RED NO. 30",
            "code": "2S42T2808B"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        }
    ],
    "indications": {
        "text": "divalproex sodium anti-epileptic indicated : treatment manic episodes associated bipolar disorder ( 1.1 ) monotherapy adjunctive therapy complex partial seizures simple complex absence seizures ; adjunctive therapy patients multiple seizure types include absence seizures ( 1.2 ) prophylaxis migraine headaches ( 1.3 )",
        "doid_entities": [
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            },
            {
                "text": "migraine (DOID:6364)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6364"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "divalproex sodium delayed-release tablets intended oral . divalproex sodium delayed-release tablets swallowed whole crushed chewed . patients informed take divalproex sodium delayed-release tablets every day prescribed . dose missed taken soon possible , unless almost time next dose . dose skipped , patient double next dose .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "divalproex sodium delayed-release tablets , usp supplied : 125 mg : orange colored , modified capsule shaped , biconvex , enteric coated tablets , imprinted `` ul 125 `` one side plain side : bottles 100\u2026\u2026\u2026\u2026\u2026\u2026ndc 68001-472-00 bottles 500\u2026\u2026\u2026\u2026\u2026\u2026ndc 68001-472-03 250 mg : pink colored , oval shaped , biconvex , enteric coated tablets , imprinted `` ul 250 `` one side plain side : bottles 100\u2026\u2026\u2026\u2026\u2026\u2026ndc 68001-473-00 bottles 500\u2026\u2026\u2026\u2026\u2026\u2026ndc 68001-473-03 500 mg : reddish pink colored , modified capsule shaped , biconvex , enteric coated tablets , imprinted `` ul 500 `` one side plain side bottles 100\u2026\u2026\u2026\u2026\u2026\u2026ndc 68001-474-00 bottles 500\u2026\u2026\u2026\u2026\u2026\u2026ndc68001-474-03 recommended storage store 20 \u00b0to 25 \u00b0c ( 68 \u00b0to 77 \u00b0f ) [ usp controlled room temperature ] . preserve tight , light resistant containers .",
    "adverseReactions": "divalproex sodium delayed-release tablets administered patients hepatic disease significant hepatic dysfunction [ ( 5.1 ) ] . divalproex sodium delayed-release tablets contraindicated patients known mitochondrial disorders caused mutations mitochondrial dna polymerase \u03b3 ( polg ; e.g . , alpers-huttenlocher syndrome ) children two years age suspected polg-related disorder [ ( 5.1 ) ] . divalproex sodium delayed-release tablets contraindicated patients known hypersensitivity [ ( 5.12 ) ] . divalproex sodium delayed-release tablets contraindicated patients known urea cycle disorders [ ( 5.6 ) ] . prophylaxis migraine headaches : divalproex sodium delayed-release tablets contraindicated women pregnant women childbearing potential using effective contraception [ ( 5.2 , 5.3 , 5.4 ) ( 8.1 ) ] .",
    "indications_original": "Divalproex sodium is an anti-epileptic drug indicated for: Treatment of manic episodes associated with bipolar disorder ( 1.1 ) Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1.2 ) Prophylaxis of migraine headaches ( 1.3 )",
    "contraindications_original": "Divalproex sodium delayed-release tablets are intended for oral administration. Divalproex sodium delayed-release tablets should be swallowed whole and should not be crushed or chewed.\n                  Patients should be informed to take divalproex sodium delayed-release tablets every day as prescribed. If a dose is missed it should be taken as soon as possible, unless it is almost time for the next dose. If a dose is skipped, the patient should not double the next dose.",
    "warningsAndPrecautions_original": "Divalproex Sodium Delayed-release Tablets, USP are supplied as:\n                  \n                  \n                     125 mg:\n                  \n                  Orange colored, modified capsule shaped, biconvex, enteric coated tablets, imprinted with \"UL 125\" on one side and plain on other side:\n                  Bottles of 100\u2026\u2026\u2026\u2026\u2026\u2026NDC 68001-472-00\n                  Bottles of 500\u2026\u2026\u2026\u2026\u2026\u2026NDC 68001-472-03\n                  \n                     250 mg:\n\n \n                  Pink colored, oval shaped, biconvex, enteric coated tablets, imprinted with \"UL 250\" on one side and plain on other side:\n                  Bottles of 100\u2026\u2026\u2026\u2026\u2026\u2026NDC 68001-473-00\n                  Bottles of 500\u2026\u2026\u2026\u2026\u2026\u2026NDC 68001-473-03\n                  \n                     500 mg:\n\n \n                  Reddish pink colored, modified capsule shaped, biconvex, enteric coated tablets, imprinted with \"UL 500\" on one side and plain on other side\n                  Bottles of 100\u2026\u2026\u2026\u2026\u2026\u2026NDC 68001-474-00\n                  Bottles of 500\u2026\u2026\u2026\u2026\u2026\u2026NDC68001-474-03\n                  \n                     Recommended storage\n                  \n                  Store at 20\n \n  \u00b0to 25\n \n  \u00b0C (68\n \n  \u00b0to 77\n \n  \u00b0F) [see USP controlled Room Temperature].\n\n \n                  Preserve in tight, light resistant containers.",
    "adverseReactions_original": "Divalproex sodium delayed-release tablets should not be administered to patients with hepatic disease or significant hepatic dysfunction\n  \n   [see Warnings and Precautions (\n   \n    5.1)].\n  \n   \n                     \n                     Divalproex sodium delayed-release tablets are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase \u03b3 (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder\n  \n   [see Warnings and Precautions (\n   \n    5.1)].\n  \n   \n                     \n                     Divalproex sodium delayed-release tablets are contraindicated in patients with known hypersensitivity to the drug\n  \n   [see Warnings and Precautions (\n   \n    5.12)].\n  \n   \n                     \n                     Divalproex sodium delayed-release tablets are contraindicated in patients with known urea cycle disorders\n  \n   [see Warnings and Precautions (\n   \n    5.6)].\n  \n   \n                     \n                     For use in prophylaxis of migraine headaches: Divalproex sodium delayed-release tablets are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception\n  \n   [see Warnings and Precautions (\n   \n    5.2,\n   \n    5.3,\n   \n    5.4) and Use in Specific Populations (\n   \n    8.1)]\n  \n   .",
    "drug": [
        {
            "name": "Divalproex Sodium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        }
    ]
}